DETECTION OF FREE-RADICALS DURING THE CELLULAR-METABOLISM OF ADRIAMYCIN

被引:19
作者
TURNER, MJ
EVERMAN, DB
ELLINGTON, SP
FIELDS, CE
机构
[1] Department of Chemistry, Wake Forest University, Winston-Salem
[2] Department of Pharmacology, Duke University Medical Center, Durham
关键词
ADRIAMYCIN; ADRIAMYCIN SEMIQUINONE FREE RADICAL; DRUG METABOLISM; SPIN TRAPPING; SUPEROXIDE;
D O I
10.1016/0891-5849(90)90018-E
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Experiments were conducted to determine which free radicals are generated during the metabolism of adriamycin (ADM) by canine tracheal epithelial (CTE) cells, guinea pig enterocytes, and rat hepatocytes. The technique employed in this study was spin trapping; the spin trap utilized was 5,5-dimethyl-1-pyrroline-1-oxide (DMPO). The spin adduct 2-hydroxy-5,5-dimethyl-1-pyrrolidinyloxyl (DMPO-OH) was observed during the metabolism of ADM by CTE cells. However, the addition of dimethyl sulfoxide to the in vitro system suggested that superoxide is initially spin trapped by the nitrone, and that the adduct 2-hydroperoxy-5,5-dimethyl-1-pyrrolidinyloxyl (DMPO-OOH) is rapidly bioreduced to afford DMPO-OH. The addition of superoxide dismutase to the system indicated that superoxide generation was primarily intracellular. The adriamycin semiquinone free radical (ADM-SQ) was produced during the metabolism by enterocytes and hepatocytes. The rate of the production of ADM-SQ was enhanced under anaerobic conditions, suggesting that molecular oxygen was responsible for the degradation of this carbon-centered free radical. However, spin trapping of oxygen radicals was not observed; this observation suggests that these reactive intermediates are not produced at concentrations sufficient for detection by spin-trapping experiments.
引用
收藏
页码:415 / 421
页数:7
相关论文
共 34 条
[1]  
Brown, Imam, Recent studies on doxorubicin and its analogues, Progress in medicinal chemistry, 21, pp. 169-236, (1984)
[2]  
Crooke, Duvernay, Mong, Molecular pharmacology of anthracyclines, Molecular actions and targets for cancer chemotherapeutic agents, pp. 137-162, (1981)
[3]  
DiMarco, Adriamycin: the therapeutic activity on experimental tumors, International symposium on adriamycin, pp. 53-63, (1972)
[4]  
Keating, McCredie, Bodey, Smith, Gehan, Freirieich, Improved prospects for long-term survival in adults with acute myelogenous leukemia, J. Am. Med. Assoc., 248, pp. 2481-2486, (1982)
[5]  
Bernard, Weill, Boiron, Jacquillat, Flandrin, Gemon, Acute promyelocytic leukemia: results of treatment by daunorubicin, Blood, 41, pp. 489-496, (1973)
[6]  
Swenerton, Legha, Smith, Hortobagyi, Gehan, Yap, Gutterman, Blumenschein, Prognostic factors in metastatic breast cancer treated with combination chemotherapy, Cancer Res., 39, pp. 1552-1562, (1979)
[7]  
Young, Lippman, De Vita, Bull, Torney, Perspectives in the treatment of breast cancer, Ann. Intern. Med., 86, (1976)
[8]  
Ozols, Young, Speyer, Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer, Cancer Res., 42, pp. 4265-4269, (1982)
[9]  
Evan, Feld, DeBoer, Osoba, Curtis, Baker, Myers, Quirt, Pritchard, Brown, Kutas, Blackstein, Ottema, Millband, Cyclophosphamide, doxorubicin, and cis-platin in the treatment of non-small cell bronchogenic carcinoma, Cancer Treat. Rep., 65, pp. 947-954, (1981)
[10]  
Knight, Lagakos, Stolbach, Colsky, Horton, Israel, Benett, Perlia, Regelson, Carbone, Adriamycin in the treatment of far-advanced lung cancer, Cancer Treat. Rep., 60, pp. 939-941, (1976)